Medidata Solutions Inc (MDSO) Receives $84.00 Average Target Price from Brokerages

Medidata Solutions Inc (NASDAQ:MDSO) has received a consensus recommendation of “Hold” from the fourteen research firms that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $84.13.

A number of research firms have issued reports on MDSO. BidaskClub lowered shares of Medidata Solutions from a “buy” rating to a “hold” rating in a report on Monday, January 7th. Zacks Investment Research downgraded shares of Medidata Solutions from a “buy” rating to a “hold” rating in a research report on Monday, January 28th. Leerink Swann began coverage on shares of Medidata Solutions in a research report on Wednesday, January 2nd. They issued a “market perform” rating and a $70.00 price objective on the stock. JPMorgan Chase & Co. downgraded shares of Medidata Solutions from a “neutral” rating to an “underweight” rating in a research report on Thursday, December 13th. Finally, TheStreet downgraded shares of Medidata Solutions from a “b” rating to a “c+” rating in a research report on Thursday, December 20th.

Medidata Solutions stock opened at $75.45 on Friday. The company has a market cap of $4.62 billion, a price-to-earnings ratio of 78.59, a price-to-earnings-growth ratio of 4.17 and a beta of 1.32. Medidata Solutions has a 52-week low of $60.10 and a 52-week high of $88.87. The company has a current ratio of 2.71, a quick ratio of 2.52 and a debt-to-equity ratio of 0.14.

Medidata Solutions (NASDAQ:MDSO) last released its earnings results on Tuesday, February 12th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.37 by $0.08. The company had revenue of $167.19 million for the quarter, compared to analyst estimates of $168.08 million. Medidata Solutions had a net margin of 8.17% and a return on equity of 10.03%. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the business earned $0.41 EPS. Equities analysts expect that Medidata Solutions will post 0.92 earnings per share for the current fiscal year.

In related news, CFO Rouven Bergmann sold 12,512 shares of the stock in a transaction on Wednesday, February 6th. The shares were sold at an average price of $75.00, for a total value of $938,400.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Robert Taylor sold 2,120 shares of the stock in a transaction on Monday, January 7th. The shares were sold at an average price of $64.70, for a total transaction of $137,164.00. Following the completion of the transaction, the director now directly owns 41,916 shares in the company, valued at $2,711,965.20. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,632 shares of company stock worth $3,126,704. Insiders own 4.70% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of MDSO. Dimensional Fund Advisors LP grew its position in shares of Medidata Solutions by 3.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 134,580 shares of the company’s stock valued at $10,841,000 after buying an additional 3,992 shares during the last quarter. Bank of Montreal Can grew its position in shares of Medidata Solutions by 20.7% in the 3rd quarter. Bank of Montreal Can now owns 29,096 shares of the company’s stock valued at $2,134,000 after buying an additional 4,995 shares during the last quarter. NJ State Employees Deferred Compensation Plan purchased a new position in shares of Medidata Solutions in the 3rd quarter valued at $293,000. Peregrine Capital Management LLC grew its position in shares of Medidata Solutions by 13.0% in the 3rd quarter. Peregrine Capital Management LLC now owns 343,883 shares of the company’s stock valued at $25,210,000 after buying an additional 39,475 shares during the last quarter. Finally, First Trust Advisors LP grew its position in shares of Medidata Solutions by 1,080.5% in the 3rd quarter. First Trust Advisors LP now owns 55,259 shares of the company’s stock valued at $4,051,000 after buying an additional 50,578 shares during the last quarter.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Featured Article: Trading Ex-Dividend

Analyst Recommendations for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.